Zai Lab (ZLAB) announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List, NRDL, released by China’s National Healthcare Security Administration, NHSA: VYVGART is renewed for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive; NUZYRA is renewed for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; and ZEJULA is renewed for the maintenance treatment of adult patients with platinum-sensitive, first-line and recurrent ovarian cancer.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB: